Alvotech (ALVO) Non-Current Debt (2020 - 2026)
Alvotech (ALVO) posted Non-Current Debt of $1.3 billion for Q1 2026, little changed on a QoQ basis from $1.3 billion in Q4 2025, and up 19.09% year-over-year from $1.1 billion in Q1 2025.
Alvotech (ALVO) Non-Current Debt (2020 - 2026) Analysis & Trends
Alvotech's Non-Current Debt history runs 7 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- Quarterly Non-Current Debt rose 19.09% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 19.09% YoY) and the FY2025 annual result came in at $1.3 billion, up 21.84% from the prior year.
- Non-Current Debt was $1.3 billion for Q1 2026 at Alvotech, roughly flat from $1.3 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.3 billion in Q1 2026 and bottomed at $56.9 million in Q2 2024.
- A 5-year average of $889.1 million and a median of $973.3 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt sank 92.77% — and 2025, when it jumped 1785.01%.
- Alvotech's Non-Current Debt stood at $744.7 million in 2022, then advanced by 23.83% to $922.1 million in 2023, then advanced by 12.34% to $1.0 billion in 2024, then increased by 21.84% to $1.3 billion in 2025, then increased by 0.39% to $1.3 billion in 2026.
- Business Quant data shows ALVO's Non-Current Debt at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | 1.27 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.27 Bn |
| Dec 31, 2025 | 1.26 Bn |
| Sep 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.07 Bn |
| Mar 31, 2025 | 1.06 Bn |
| Dec 31, 2024 | 1.04 Bn |
| Sep 30, 2024 | 1.01 Bn |
| Jun 30, 2024 | 56.88 Mn |
| Mar 31, 2024 | 940.59 Mn |
| Dec 31, 2023 | 922.13 Mn |
| Jun 30, 2023 | 786.18 Mn |
| Mar 31, 2023 | 770.66 Mn |
| Dec 31, 2022 | 744.65 Mn |
| Jun 30, 2022 | 438.19 Mn |
| Dec 31, 2021 | 398.14 Mn |
| Dec 31, 2020 | 565.40 Mn |